Hospital care model aims to treat opioid addiction and serious infections together

NCT ID NCT04180020

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests a care model where hospitalized adults with opioid use disorder and a serious infection receive long-acting injectable buprenorphine from their infectious disease doctors, alongside infection treatment. The goal is to keep patients on effective medication for opioid use disorder after discharge. Participants are randomly assigned to this new model or to standard care, and researchers track whether they stay on treatment at 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
long-acting injectable buprenorphine
What this could lead to
If successful, this model could improve treatment retention for people with opioid use disorder and serious infections, reducing relapse and complications.
What could go wrong
This is a relatively small study testing a care model, not a new drug. Results may not apply broadly, and the intervention depends on hospital resources and patient willingness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania, 17033, United States

  • Prisma Health

    Greenville, South Carolina, 29650, United States

  • Yale New Haven Hospital

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.